Canada Markets open in 9 hrs 17 mins

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
41.42+1.65 (+4.15%)
At close: 04:00PM EDT
37.48 -3.94 (-9.51%)
After hours: 06:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close39.77
Open40.17
Bid36.62 x 900
Ask36.00 x 900
Day's Range39.48 - 41.46
52 Week Range19.86 - 46.16
Volume472,376
Avg. Volume565,219
Market Cap6.099B
Beta (5Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-1.54
Earnings DateMar 22, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.83
  • GlobeNewswire

    Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

    CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced a private offering of $250.0 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of

  • GlobeNewswire

    Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of

  • GlobeNewswire

    Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

    Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer’s disease psychosis Panic disorder selected as second indication for darigabat, planning underway for Phase 2 proof-of-concept Cash, cash equivalents and marketable securities of $531M as of June 30, 2022, expected to support operations into 2024 Conference call today at 8:00 a.m. E